If what I present came true how does CBAI benefit? HIPPAA Law makes CBAI the brokerage firm and Mediary in the transaction. CBAI has the list and is no way violating contacting its client/customer; even as a New Brokerage Firm of sorts. CBAI isn't the seller the owner of the stored sample is. CBAI could undercut the global public registry. The value minded customers with $2000 to store could look at this model I propose as a $2000 upfront piece of mind medical expense but should their child and family not need that sample in the immediate future after the birth of their child then place it on the CBAI private global registry for sale. The insurance companies, pharmas and hospitals will need to rely on the storage business to perform this task - which makes the storage entity a very important cog to the entire gear. HIPPAA Law makes it so.
This means CBAI and other larger private banking institutions become: Adult Stem Cell Brokerage Warehouses for their client; "Us." It sweeps the wind out of the public donor registry and puts the money back in the hands of the people who created the adult stem cells that they sell each day; the parents & their child. An entirely new revs engine model not ever done before on the planet! That is what I propose CBAI should do to become a $100/pps company today. Too macro or just right?
What percentage of families after paying $2,000 for private storage would jump at the opportunity of maybe getting 5x the initial investment back if there isn't any present medical need for that valuable sample they stored? More than a few. How much do parents get back when they donate it to the public registry? Donut hole but the gratification they may have made a difference. This model may even remove the risk associated with the processing downfall associated with the public donor tank. Not all samples are viable; hence the 1 out of 10 stored in the public model. The parents who pay know quickly after their sample is processed whether it is viable. CBAI already performs that check so no added cost. Maybe in this excersize the family pays for those tests, a nominal fee that is less than $2000, should their sample not be viable. For those famlies that bank private and then sell their stem through the proposed CBAI brokerage to an insurance company for transplant they get a benefit of knowing their sample saved a life and they get their $2k investment plus may upwards of 5x their investment back. How much is the EU blood going to be worth if stored privately with an HIV antigen present? Maybe that sample is worth $100k so the family gets 10x its intial investment back depending on what CBAI is able to get on the private registry market. It's a win-win situation in this model for CBAI. It is doing what the public registry has done for years so there should not be any revolt against it.
If CBAI became this new brokerage and received a commission for being that mediary we could be talking about an entirely new untapped arm of revs. Again, the public tank gets upwards of $35k per sample.
What I propose likely circumvents the previous Pharma litigation issue too. I am surprised the privates never thought of themselves as brokers. "They don't own the sample... never have." If they broker the sale of the sample as the Agent representing client x; who still owns the sample in the sale transaction? The client! It circumvents the Pharma argument entirely because the private even as a brokerage firm never sold the sample the private storage client is the seller.
What are your thoughts? It happens everyday in real property transactions. No difference and no violation of prior pharma patent disputes.
News 
Market Data 
Discover 
